NOVONIX Ltd Files 6-K Report

Ticker: NVNXF · Form: 6-K · Filed: Jun 4, 2024 · CIK: 1859795

Novonix LTD 6-K Filing Summary
FieldDetail
CompanyNovonix LTD (NVNXF)
Form Type6-K
Filed DateJun 4, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-issuer, disclosure

TL;DR

NOVONIX filed a 6-K on June 4th with an Appendix 2A, standard foreign issuer report.

AI Summary

NOVONIX Limited filed a Form 6-K on June 4, 2024, reporting information for the month of June 2024. The filing includes Exhibit 99.1, which is Appendix 2A (Application). The company is incorporated in Australia and its fiscal year ends on December 31.

Why It Matters

This filing provides an update on the company's activities and regulatory disclosures, which is important for investors tracking its progress and compliance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (Form 6-K) that does not appear to contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that are required to disclose certain information to the public, such as material events or information that is made public in their home country.

What specific exhibit is included with this 6-K filing?

This 6-K filing includes Exhibit 99.1, which is described as Appendix 2A (Application).

When is NOVONIX Limited's fiscal year end?

NOVONIX Limited's fiscal year ends on December 31.

Where is NOVONIX Limited's principal executive office located?

NOVONIX Limited's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.

Does NOVONIX Limited file its annual reports under Form 20-F or Form 40-F?

NOVONIX Limited indicates that it files its annual reports under cover of Form 20-F.

Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-06-04 16:10:05

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: June 4, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing